UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Journal of clinical oncology, 2021-06, Vol.39 (17), p.JCO2100306-1855

2021

Volltextzugriff (PDF)

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic oncology, 2019-03, Vol.152 (3), p.548-553

2019

Volltextzugriff (PDF)

The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors

The American journal of surgical pathology, 2008-01, Vol.32 (1), p.98-102

2008

Volltextzugriff (PDF)

Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N

Gynecologic oncology, 2015-07, Vol.138 (1), p.24-29

2015

Volltextzugriff (PDF)

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Journal of clinical oncology, 2016-07, Vol.34 (19), p.2279-2286

2016

Volltextzugriff (PDF)

Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial

Journal of clinical oncology, 2024-07, Vol.42 (20), p.2425-2435

2024

Volltextzugriff (PDF)

A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial

Gynecologic oncology, 2015-09, Vol.138 (3), p.513-518

2015

Volltextzugriff (PDF)

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic oncology, 2015-09, Vol.138 (3), p.507-512

2015

Volltextzugriff (PDF)

Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study

Gynecologic oncology, 2018-08, Vol.150 (2), p.300-305

2018

Volltextzugriff (PDF)

Postoperative rehabilitation following surgical staging of endometrial cancer: A hidden cost savings of robotic surgery?

Gynecologic oncology, 2015-12, Vol.139 (3), p.599-600

2015

Volltextzugriff (PDF)

Vaginal Use of the Flexi-Seal Fecal Management System for Non-Surgical Management of Female Genital Tract Fistula

Gynecologic oncology, 2015-12, Vol.139 (3), p.601-601

2015

Volltextzugriff (PDF)

Association of primary breast cancer of the vulva with hereditary breast and ovarian cancer

Journal of clinical oncology, 2013-05, Vol.31 (13), p.e231-e232

2013

Volltextzugriff (PDF)

Development and Impact of Human Papillomavirus Vaccines

Clinical obstetrics and gynecology, 2013-03, Vol.56 (1), p.10-16

2013

Volltextzugriff (PDF)

Cyclooxygenase-2 in cervical neoplasia: A review

Gynecologic oncology, 2008-04, Vol.109 (1), p.140-145

2008

Volltextzugriff (PDF)

54 Patterns of genomic testing for epithelial ovarian cancer across a large community-based health care network – a real world experience

Gynecologic oncology reports, 2022-12, Vol.44, p.S26-S26

2022

Volltextzugriff (PDF)

28 Factors impacting genomic testing rates among epithelial ovarian cancer patients across a large community-based healthcare system

Gynecologic oncology reports, 2022-12, Vol.44, p.S13-S13

2022

Volltextzugriff (PDF)

53 Frequency of homologous recombination deficiency in a large community-based cohort of epithelial ovarian cancer cases

Gynecologic oncology reports, 2022-12, Vol.44, p.S25-S26

2022

Volltextzugriff (PDF)

Growth Hormone Promotes the Association of Transcription Factor STAT5 with the Growth Hormone Receptor

The Journal of biological chemistry, 1996-08, Vol.271 (33), p.19768-19773

1996

Volltextzugriff (PDF)

Identification of growth hormone receptor (GHR) tyrosine residues required for GHR phosphorylation and JAK2 and STAT5 activation

Molecular endocrinology (Baltimore, Md.), 1996-10, Vol.10 (10), p.1249-1260

1996

Volltextzugriff (PDF)

Surgical management and postoperative treatment of endometrial carcinoma

Reviews in obstetrics and gynecology, 2008, Vol.1 (3), p.97-105

2008

Volltextzugriff (PDF)

Community oncologists' perceptions and utilization of large-panel genomic tumor testing

BMC cancer, 2021-11, Vol.21 (1), p.1273-1273, Article 1273

2021

Volltextzugriff (PDF)

Patients' Expectations of Benefits From Large-Panel Genomic Tumor Testing in Rural Community Oncology Practices

JCO precision oncology, 2021 (5), p.1554-1562

2021

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors

Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial

A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study

Postoperative rehabilitation following surgical staging of endometrial cancer: A hidden cost savings of robotic surgery?

Vaginal Use of the Flexi-Seal Fecal Management System for Non-Surgical Management of Female Genital Tract Fistula

Association of primary breast cancer of the vulva with hereditary breast and ovarian cancer

Development and Impact of Human Papillomavirus Vaccines

Cyclooxygenase-2 in cervical neoplasia: A review

54 Patterns of genomic testing for epithelial ovarian cancer across a large community-based health care network – a real world experience

28 Factors impacting genomic testing rates among epithelial ovarian cancer patients across a large community-based healthcare system

53 Frequency of homologous recombination deficiency in a large community-based cohort of epithelial ovarian cancer cases

Growth Hormone Promotes the Association of Transcription Factor STAT5 with the Growth Hormone Receptor

Identification of growth hormone receptor (GHR) tyrosine residues required for GHR phosphorylation and JAK2 and STAT5 activation

Surgical management and postoperative treatment of endometrial carcinoma

Community oncologists' perceptions and utilization of large-panel genomic tumor testing

Patients' Expectations of Benefits From Large-Panel Genomic Tumor Testing in Rural Community Oncology Practices

Suchergebnisse filtern